TY - JOUR T1 - Screening for Psychotherapeutic Medication Misuse in Primary Care Patients: Comparing Two Instruments JF - The Journal of the American Board of Family Medicine JO - J Am Board Fam Med SP - 272 LP - 278 DO - 10.3122/jabfm.2019.02.180172 VL - 32 IS - 2 AU - Sebastian T. Tong AU - Kathryn M. Polak AU - Michael F. Weaver AU - Gabriela C. Villalobos AU - Wally R. Smith AU - Dace S. Svikis Y1 - 2019/03/01 UR - http://www.jabfm.org/content/32/2/272.abstract N2 - Introduction: Prescription psychotherapeutic medication misuse is a growing problem in the United States, but no method exists to routinely screen for this in primary care. Our study sought to (1) describe the prevalence of prescription psychotherapeutic medication misuse in primary care and the characteristics of patients who misuse and (2) compare 2 screening instruments modified to identify prescription medication misuse in primary care.Methods: Primary care patients from underserved, urban clinics within a health system completed anonymous computer-directed health screens that included standard questions about prescription medication misuse. They were also administered the 4-item Cut down, Annoyed, Guilty, and Eye-opener questionnaire modified to focus on prescription medications (RxCAGE) and a 6-item Prescription Opioid Misuse Index (POMI-e) expanded to include other prescription medications.Results: Of 2,339 respondents, 15.3% were positive for at least 2 items on the RxCAGE and 18.6% were positive for at least 2 items on the POMI-e. Using our computer-directed health screen as a comparison, we found that POMI-e had a higher area under the curve (0.63). A positive POMI-e was associated with being male, white and unemployed, having depression and anxiety, and currently using illicit substances, smoking, and misusing alcohol.Conclusions: Rates of prescription medication misuse were substantial with both RxCAGE and POMI-e showing promise as screening instruments. Future studies are needed to test prescription medication misuse screening tools in broader populations and pilot interventions for those screening positive. ER -